FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder
- Sunday, January 15, 2023, 7:13
- PR Newswire
- Add a comment
Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United States. PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ — Luye Pharma Group (Luye Pharma), an…
About the Author
admin has written 20655 stories on this site.